Impact of the Number of Anti-Thrombosis Agents in Hemodialysis Patients: BOREAS-HD2 Study

Impact of the Number of Anti-Thrombosis Agents in Hemodialysis Patients: BOREAS-HD2 Study

Background/Aims: Relationships between the number of anti-thrombosis agents, clinical benefits and adverse events in hemodialysis (HD) patients are unclear. Methods: All patients on HD in 22 institutes (n = 1,071) were enrolled and followed up for 3 years. After exclusion of patients with missing da...

Full description

Bibliographic Details
Main Authors: Marenao Tanaka, Norihito Moniwa, Hirofumi Ohnishi, Tomohisa Yamashita, Masayuki Koyama, Yufu Gocho, Keitaro Nishizawa, Yukishige Kimura, Hirohito Sugawara, Sayaka Murakami, Yusuke Okazaki, Masato Furuhashi, Hideaki Yoshida, Tetsuji Miura
Format: Article
Language:English
Published: Karger Publishers 2017-09-01
Series:Kidney & Blood Pressure Research
Subjects:
Hemodialysis
Mortality
Hemorrhagic event
Anti-thrombosis agent
Online Access:http://www.karger.com/Article/FullText/480487

Internet

http://www.karger.com/Article/FullText/480487

Similar Items